Eurofins Expands Kidney Transplant Diagnostics Offering Through Viracor TRAC™
Viracor Eurofins, a leading U.S. transplant diagnostics laboratory, announced it has begun offering a proprietary donor derived cell-free DNA (dd-cfDNA) assay, Viracor TRAC™, to complement its suite of testing supporting successful outcomes for those patients with kidney transplants.
The announcement of TRAC Kidney continues Viracor’s 30 year commitment to scientific innovation in clinical diagnostics and further enhances Viracor’s comprehensive transplant diagnostic portfolio. When combined with Eurofins’ market-leading pre-transplant laboratory, VRL, and newly acquired Transplant Genomics, which provides testing to detect subclinical rejection, Eurofins believes it provides hospitals, physicians and organ procurement organizations the most comprehensive transplant testing menu in the U.S.
TRAC is a non-invasive liquid biopsy with similar performance characteristics to other dd-cfDNA assays currently on the market. The current gold standard method of rejection diagnosis and surveillance is organ biopsy, an invasive technique that suffers from high cost and potentially multiple complications for the patient. Viracor has invested in two ongoing prospective and one retrospective clinical trial to further develop clinical data to support the use of the test. Through its work with the American Medical Association/CPT®, Viracor Eurofins has secured a Proprietary Laboratory Analyses (PLA) code for Viracor TRAC™.
Today we are pleased to add TRAC, our innovative dd-cfDNA assay to enhance our portfolio of diagnostic tests for renal transplant management. On November 25th, Eurofins Transplant Genomics introduced TruGraf for detection of subclinical kidney rejection and now we are introducing TRAC for detection of acute kidney rejection. With our focus on clinical diagnostics and transplantation, we believe that we provide the most comprehensive testing solutions from pre-transplant donor-matching to detection and monitoring various post-transplant conditions, including organ rejection, infection and therapeutic immunosuppression. In striving for diagnostic efficiency and improved cost of care, we believe that TRAC will make a big difference for the constituencies we serve – transplant patients, healthcare providers and payers.
About Viracor Eurofins
As a member of Eurofins Scientific, a global leader in laboratory services for specialty clinical diagnostics, discovery pharmacology and supporting clinical studies, Viracor serves many leading biopharmaceutical companies and a wide range of clinical and academic customers in the U.S. With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to helping medical professionals, transplant teams, reference laboratories and biopharmaceutical companies get results faster, when it matters most.
Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit https://www.eurofins.com/ and https://www.viracor-eurofins.com/ .
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is a scientific leader in food, environment, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the leading global emerging players in specialty clinical diagnostic testing. With about 45,000 staff in more than 800 laboratories across 47 countries, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).